Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?: A discussion based on recent recommendations from the European agency for evaluation of medicinal products regarding third generation oral contraceptive pills

References

• Rock J, Garcia CR, Pincus G. Synthetic progestins in the normal human menstrual cycle. Rec Prog Hormone Res, 1957; 13: 323.
   Google Scholar
• Oddens B, Milsom I. Contraceptive practice and attitudes in Sweden. Acta Obstet Gynecol Scand 1996, 1994; 75: 932–40.
   Google Scholar
• Larsson G, Milsom I, Sundell G, Andersch B, Blohm F. A longitudinal study of birth control and pregnancy outcome in a Swedish population. Contraception, 1997; 56: 9–16.
   Google Scholar
• Vessey MP. The Jephcott Lecture: an overview of the benefits and risks of combined oral contraceptives. In: Mann, RD (ed.): Oral Contraceptives and Breast Cancer. London: Parthenon Publishing Group, 1989: 121–32.
   Google Scholar
• Inman WHW, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives. a report to the Committee on Safety of Drugs. Br Med J, 1970; 2: 203–9.
   Google Scholar
• Meade TW et al. Progestogens and cardiovascular actions associated with oral contraceptives and a comparison of the safety of 50 and 30 ug oestrogen preparations. Br Med J, 1980; 20: 1157.
   Google Scholar
• Böttiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet, 1980; 1: 1097–101.
   Google Scholar
• World Health Organisation Collaborative Study on cardiovascular disease and steroid hormone contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet, 1995; 346: 1582–8.
   Google Scholar
• Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of ideopathic cardiovascular death and non fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet, 1995; 346: 1589–93.
   Google Scholar
• Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J, 1996; 312: 83–7.
   Google Scholar
• Vandenbroucke JP, Rosendaal FR. End of the line for ‘third-generation-pill' Lancet. 1997; 349: 1113–4.
   Google Scholar
• Lidegaard Ø, Milsom I. Oral contraceptives and venous thromboembolism. Lancet, 1997; 349: 1621.
   Google Scholar
• EMEA. Committee for Proprietary Medicinal Products (CPMP) public assessment report on combined oral con-traceptives and venous thromboembolism. (http://www.emea.eu.int/pdfs/human/regaffair/0220101en.pdf).
   Google Scholar
• Vasilakis-Scaramozza Jick H. Risk of thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 1427–9.
   Google Scholar
• Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenner PF, Mishell DR Jr. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol, 1982; 144: 511–8.
   Google Scholar
• Fotherby KA. metabolic assessment of different oral contraceptives. J Obstet Gynecol (supplement 2), 1983; 77.
   Google Scholar
• Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996; 51: 188–215.
   Google Scholar
• Speroff L, DeCherney A. and The Advisory Board for the New Progestins. Evaluation of a new generation of oral contraceptives. Obstet Gynecol, 1993; 81: 1034–47.
   Google Scholar
• Mainwaring R, Hales HA, Stevenson K, Hatasaka HH, Poulson AM, Parker Jones K et al. Metabolic parameter, bleeding, weight changes US women using progestin only contraceptives Contraception, 1995; 51: 149–53.
   Google Scholar
• Jia MC, Zhou LY, Ren S, Dong L, Xiao B. Serum SHBG levels during normal menstrual cycle and after insertion of levonorgestrel-releasing IUD. Advances in Contraception, 1992; 8: 33–40.
   Google Scholar
• Pakarinen P Lahteenmaki P, Rutanen EM. The effect of intrauterine and oral levonogestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1. Acta Obstet Gynecol Scand, 1999; 78: 423–8.
   Google Scholar
• Mäkäräinen L, van Beek A, Tuomivaara L, Asplund B, Coelingh Bennink H. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril, 1998; 69: 714–21.
   Google Scholar
• Crona N, Silfverstolpe G, Samsioe G. Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol. Contraception, 1984; 29: 261–70.
   Google Scholar
• Ball MJ, Ashwell E, Jackson M, Gillmer MDG. Comparison of two triphasic contraceptives with different progestogens: effects on metabolism and coagulation proteins. Contraception, 1990; 41: 363–76.
   Google Scholar
• Song S, Jun-kang C, Pei-juan Y, Mei-li H, La-mei L, Bao-chuan F, Rekers H, Fotherby K. A crossover study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonogestrel. Contraception, 1992; 45: 523–32.
   Google Scholar
• Nielsen CH, Poulsen HK, Teisner B, Thorsen P, Hau J, Westergaard JG. Changes in blood levels of proteinase inhibitors, pregnancy zone protein, steroid carriers and complement factors induced by oral contraceptives. European J Obstet Gynecol Reprod Biol, 1993; 51: 63–71.
   Google Scholar
• Kuhl H, Jung-Hoffmann C, Fitzner M. Produg versus drug effects of 150 microg desogestrel or 3-keto-desogestrel in combination with 30 microg ethinylestradiol on hormonal parameters. relevance peak serum level 3-keto-desogestrel. Horm Res, 1995; 44: 126–32.
   Google Scholar
• Åkerlund M, Almström E, Högstedt S, Nabrink M. Oral contraceptive tablets containing 20 and 30 microg of ethinyl estradiol with 150 microg desogestrel: their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone. Acta Obstet Gynecol Scand, 1994; 73: 136–43.
   Google Scholar
• Song Si, Jun-kang C, Mei-li H, Fotherby K. Effect of some oral contraceptives on serum concentrations of sex hormone binding globulin and ceruloplasmin. Contraception, 1989; 39: 385–99.
   Google Scholar
• Kuhnz W, Staks T, Jütting G. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. Contraception, 1994; 50: 563–79.
   Google Scholar
• Boyd RA, Zegarac EA, Posvar EL, Flack MR. Minimal androgenic activity of a new oral contraceptive containing norethindrone acetate and graduated doses of ethinyl estradiol. Contraception, 2001; 63: 71–6.
   Google Scholar
• Moutos D, Smith S, Zacur H. The effect of monophacis combinations of ethinyl estradiol and norethindrone on gonadotropins, androgens and sex hormone binding globulin: a randomized trial. Contraception, 1995; 52: 105–9.
   Google Scholar
• van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA, Thijssen JHH. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception, 1990; 41: 345–52.
   Google Scholar
• Fotherby K, Trayner I, Longthorne PN, Lee B, Watson HR. Metabolic investigations with femodene – an oral contraceptive containing gestodene and ethinyloestradiol. Contraception, 1987; 35: 323–37.
   Google Scholar
• Palatsi R, Hirvensalo E, Liukko P Malmiharju T, Mattila L et al. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives. Acta Derm Venereol (Sthlm), 1984; 64: 517–23.
   Google Scholar
• Bergink EW, Holma P Pyörälä T. Effects of oral contraceptive combinations containing levonorgestrel or desogestrel on serum proteins and androgen binding. Scand J Clin Laboratory Invest, 1981; 41: 663–8.
   Google Scholar
• Larsson-Cohn U, Fåhraeus L, Wallentin L, Zador G. Effects of the estrogenicity of levonorgestrel/ethinylestradiol combinations on the lipoprotein status. Acta Obstet Gynecol Scand Supplement, 1982; 105: 37–40.
   Google Scholar
• Odlind V, Weiner E, Victor A, Johansson EDB. Effects on sex hormone binding globulin of different oral contraceptives containing norethisterone and lynestrenol. Br J Obstet Gynecol 1980, 1982; 87: 416–21.
   Google Scholar
• Janaud A, Rouffy J, Upmalis D, Dain MP. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or le-vonorgestrel. Acta Obstet Gynecol Scand, 1992; 71: 33–8.
   Google Scholar
• London RS, Chapdelaine A, Upmalis D, Olson W, Smith J. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand, 1992; 71: 9–14.
   Google Scholar
• Thorneycroft IH, Stanczyk FZ, Bradshaw KD, Ballagh SA, Nichols M, Weber ME. Effect of low-dose oral contraceptives on androgenic markers and acne. Contraception, 1999; 60: 255–62.
   Google Scholar
• Wiegratz I, Jung-Hoffmann C, Kuhl H. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins. Contraception, 1995; 51: 341–6.
   Google Scholar
• Kuhl H, Jung-Hoffmann C, Weber J, Boehm BO. The effect of a biphasic desogestrel-containing oral contraceptive on carbohydrate metabolism and various hormonal parameters. Contraception, 1993; 47: 55–68.
   Google Scholar
• Dieben T, Vromans L, Theeuwes A, Coelingh Bennink HJT. The effects of CTR-24, a biphasic oral contraceptive combination, compared to diane-35 in women with acne. Contraception, 1994; 50: 373–82.
   Google Scholar
• Knopp RH, Broyles FE, Cheung M, Moore K, Marcovina S, Chandler WL. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonogestrel. Contraception, 2001; 63: 1–11.
   Google Scholar
• Gaspard UJ, Romus MA, Gillain D, Duvivier J, Demey-Ponsart E, Franchimont P. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception, 1983; 27: 577–90.
   Google Scholar
• Hammond GL, Langley MS, Robinson PA, Nummi S, Lund L. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing deso-gestrel or levonogestrel. Fertil Steril, 1984; 42: 44–51.
   Google Scholar
• van den Ende A, Geurts TBP, Kloosterboer HJ. A randomized cross-over study comparing pharmacodynamic and metabolic variables of a new combiphasic and well-established triphasic oral contraceptive. Eur J Contracept Reprod Health Care, 1997; 2: 173–80.
   Google Scholar
• Chapdelaine A, Desmarais JL, Derman RJ. Clinical evidence of the minimal androgenic activity of norgestimate. IntJ Fertil, 1989; 34: 347–52.
   Google Scholar
• Lepot MR, Gaspard UJ. Metabolic effects of two low-dose triphasic oral contraceptives containing ethinyl estradiol and levonorgestrel or gestodene. International J Fertil Supplement, 1987: 15–20.
   Google Scholar
• Liukko P, Erkkola R, Bergink EW Progestagen-dependent effect on some plasma proteins during oral contraception. Gynecol Obstet Invest, 1988; 25: 118–22.
   Google Scholar
• Blode H, Wuttke W, Loock W, Röll G, Heithecker R. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur J Contracept Reprod Health Care, 2000; 5: 256–64.
   Google Scholar
• Medical Products Agency registration file, Uppsala Sweden.
   Google Scholar
• Cullberg G. Pharmacodynamic studies on desogestrel administered alone and in combination with ethinylestradiol. Acta Obstet Gynecol Scand Supplement, 1984; 133: 1–33055.
   Google Scholar
• Tanis BC, van den Bosch MAAJ, Kemmeren J, Manger Cats V Helmerhorst FM et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med, 2001; 345: 1787–93.
   Google Scholar
• Middeldorp S, Meinardi JR, Koopman MM, van Pampus EC, Hamulyak K et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med, 2001; 135: 322–7.
   Google Scholar
• Rosing J, Tans G, Nicolaes GA, Thomassen MC, van Oerle R, van der Ploeg et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second-and third-generation oral contraceptives. Br J Haematol, 1997; 97: 233–8.
   Google Scholar
• Tans G, Curvers J, Middeldorp S, Thomassen MC, Meijers JC et al. A randomized cross-over study on the effects of levonorgestrel-and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost, 2000; 84: 1–3.
   Google Scholar
• Rosing J, Middeldorp S, Curvers J, Christella M, Thomass-en LG et al. Low-dose oral contraceptives and acquired resistance to activated protein C. a randomised cross-over study. Lancet, 1999; 354: 2036–40.
   Google Scholar
• Kluft C, de Maat MP, Heinemann LA, Spannagl M, Schramm W. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation. Lancet, 1999; 354: 832–3.
   Google Scholar